SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-068964
Filing Date
2024-08-14
Accepted
2024-08-14 16:01:24
Documents
69
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0210571-10q_tffpharma.htm   iXBRL 10-Q 807724
2 CERTIFICATION ea021057101ex31-1_tffpharma.htm EX-31.1 10878
3 CERTIFICATION ea021057101ex31-2_tffpharma.htm EX-31.2 11013
4 CERTIFICATION ea021057101ex32-1_tffpharma.htm EX-32.1 5183
5 GRAPHIC image_001.jpg GRAPHIC 2931
  Complete submission text file 0001213900-24-068964.txt   4416755

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20240630.xsd EX-101.SCH 51225
7 XBRL CALCULATION FILE tffp-20240630_cal.xml EX-101.CAL 29262
8 XBRL DEFINITION FILE tffp-20240630_def.xml EX-101.DEF 207189
9 XBRL LABEL FILE tffp-20240630_lab.xml EX-101.LAB 387510
10 XBRL PRESENTATION FILE tffp-20240630_pre.xml EX-101.PRE 206176
72 EXTRACTED XBRL INSTANCE DOCUMENT ea0210571-10q_tffpharma_htm.xml XML 401387
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 241207276
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)